2 Minutes
Researchers are exploring a new therapeutic route to restore brain energy balance that avoids risks linked to over-the-counter NAD+ precursor supplements. Instead of pushing NAD+ levels artificially high, scientists are testing a compound called P7C3-A20 that helps cells preserve healthy NAD+ homeostasis during extreme stress—supporting recovery without overshooting normal levels.
Why this strategy is not just another supplement
Many popular NAD+-boosting supplements elevate cellular NAD+ broadly. Animal studies suggest that excessive NAD+ can create an environment that favors cancer growth. The P7C3-A20 approach is different: it stabilizes NAD+ under stress, preventing dangerous spikes while maintaining the energy supply neurons need to survive and function.
Clinical promise and patient-care considerations
“This distinction matters for patient safety,” said Dr. Pieper, one of the investigators behind the work. Restoring brain energy balance may give clinicians a concrete target for therapies aimed at reversing neurodegenerative decline rather than only managing symptoms.
What the research team will test next
- Move the therapy into carefully designed human clinical trials to see if the animal-model benefits translate to people.
- Pinpoint which elements of brain energy balance—mitochondrial function, NAD+ turnover, or metabolic signaling—are most critical for recovery.
- Explore complementary strategies that might enhance reversal of Alzheimer’s pathology.
- Evaluate whether this recovery-oriented approach works for other chronic, age-related neurodegenerative diseases.
From lab bench to commercial development
Glengary Brain Health, a Cleveland-based company co-founded by Dr. Pieper, is commercializing the technology. The move toward industry partnership reflects growing interest in translational paths that can bridge preclinical results and human trials.
Ultimately, the aim is to offer a therapeutic that corrects energy deficits in vulnerable brain cells without the carcinogenic risk suggested by unchecked NAD+ elevation. For clinicians and patients alike, that balance—between efficacy and safety—will determine whether this strategy becomes a new tool against Alzheimer’s and related disorders.
Source: scitechdaily
Leave a Comment